Unknown

Dataset Information

0

Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia.

ABSTRACT:

SUBMITTER: Sharman JP 

PROVIDER: S-EPMC8979808 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia.
| S-EPMC11794137 | biostudies-literature
Unknown Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
| S-EPMC8151619 | biostudies-literature
Unknown Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN.
| S-EPMC12824692 | biostudies-literature
Unknown Acalabrutinib plus Obinutuzumab in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia.
| S-EPMC8176161 | biostudies-literature
Unknown Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.
| S-EPMC10113251 | biostudies-literature
Unknown P637: TIME-LIMITED TREATMENT WITH ACALABRUTINIB PLUS OBINUTUZUMAB IN TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: EARLY RESULTS OF AN ONGOING PHASE 2 TRIAL
| S-EPMC10428860 | biostudies-literature
Unknown Acalabrutinib in treatment-naive chronic lymphocytic leukemia.
| S-EPMC8670015 | biostudies-literature
Unknown Long-term outcomes of chemoimmunotherapy with obinutuzumab/chlorambucil in chronic lymphocytic leukemia.
| S-EPMC12142505 | biostudies-literature
Unknown Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naive Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.
| S-EPMC11996140 | biostudies-literature
Unknown Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study.
| S-EPMC9719965 | biostudies-literature